Suganil 5 mg (Tablet)

Indications

• Treatment of non insulin dependent diabetes melitus (NIDDM)

Pharmacology

• Reduces blood sugar concentration by stimulating insulin secretion
• Reduces basal hepatic glucose production
• Enhances peripheral insulin action at target sites

Dosage & Administration

• Initial stabilization dosage of 2.5 mg half tablet
• Maintenance therapy with 2.5 mg half tablet
• Maximum dosage of 10 mg
• Changeover from insulin to Glibenclamide guidelines

Interaction

• Potential enhanced hypoglycemic effect with alcohol, cyclophosphamide, dicoumarol, monoamino oxidase inhibitors, phenylbutazone, propranolol, and certain long-acting sulphonamides

Contraindications

• Severe metabolic de-compensation with acidosis, pre-comatose states and diabetic coma
• Severe renal or hepatic dysfunction
• Serious impairment of typhoid or adrenal function
• Pregnancy
• Diabetes mellitus complicated by fever, trauma or gangrene

Side Effects

• Nausea
• Vomiting
• Epigastric pain
• Dizziness
• Weakness
• Paraesthesia
• Headache
• Allergic skin reactions
• Haemopoietic reactions

Pregnancy & Lactation

• No known ill consequences in human pregnancy
• No evidence of transfer to human milk

Precautions & Warnings

• Emphasis on weight reduction as integral part of diabetic treatment

Overdose Effects

• Symptoms of hypoglycaemia
• Management involving oral glucose and adjustment of drug dosage and/or meal patterns

Therapeutic Class

• Sulfonylureas

Storage Conditions

• Store in a dry place below 30˚ C

Related Brands